MNPR Monopar Therapeutics
Pharmaceutical Preparations · Nasdaq · SEC CIK 1645469 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-15.3%
ROA-15.0%
ROIC (approx.)-45.6%
Asset turnover—
Leverage & solvency
Liabilities / assets2.4%
Debt / equity0.00x
Current ratio43.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | — | — | — | — | — |
| R&D expense | $4.44M | $4.77M | $3.49M | $3.94M | $2.59M | $1.73M | $1.64M | $9.92M |
| SG&A expense | $3.03M | $1.88M | $1.74M | $2.21M | $1.50M | $1.50M | $1.58M | $1.15M |
| Operating income | -$7.47M | -$6.64M | -$5.23M | -$6.16M | -$4.09M | -$3.23M | -$3.22M | -$11.07M |
| Net income | -$6.20M | -$5.31M | -$3.89M | -$5.20M | -$3.44M | -$2.45M | -$2.62M | -$10.93M |
| EPS (basic) | -0.72 | -0.62 | -0.46 | — | -0.48 | -0.35 | -0.38 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $52.63M | $52.76M | $52.54M | $61.83M | $127.68M | $39.50M | $39.71M | $45.82M |
| Short-term investments | $52.49M | $52.61M | $52.37M | $60.88M | $127.50M | $39.33M | $39.51M | $45.53M |
| Current assets | $129.88M | $134.76M | $137.74M | $140.46M | $144.09M | $53.75M | $55.08M | $60.29M |
| Total assets | $130.25M | $134.98M | $137.98M | $140.72M | $144.20M | $53.87M | $55.09M | $60.29M |
| Current liabilities | $2.98M | $4.02M | $2.46M | $2.74M | $2.57M | $1.58M | — | $5.25M |
| Total liabilities | $3.18M | $4.12M | $2.59M | $2.89M | $2.64M | $1.66M | $1.49M | $5.25M |
| Shareholders' equity | $127.07M | $130.85M | $135.39M | $137.83M | $141.56M | $52.20M | $53.59M | $55.04M |
| Shares outstanding | 6.76M | 6.71M | 6.70M | 6.69M | 6.66M | 6.13M | 6.12M | 6.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.17M | -$3.25M | -$3.47M | -$3.37M | -$2.09M | -$1.08M | -$5.66M | -$2.00M |
| Investing cash flow | $5.46M | $4.12M | -$5.58M | -$62.19M | -$2.13M | $1.19M | -$325,828 | -$14.34M |
| Financing cash flow | $586,232 | -$647,389 | -$200,203 | -$384,680 | $92.39M | -$316,845 | -$115,682 | $56.14M |
| Stock-based compensation | $2.04M | $1.43M | $1.69M | $1.10M | $1.10M | $1.28M | $1.36M | $278,612 |
| Share buybacks | — | — | — | $0 | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.